|
US6875584B1
(en)
*
|
1999-03-02 |
2005-04-05 |
University Of Georgia Research Foundation, Inc. |
Prophylactic and therapeutic immunization against protozoan infection and disease
|
|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7550143B2
(en)
*
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US7534866B2
(en)
*
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7527787B2
(en)
*
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
KR101017732B1
(ko)
*
|
2002-03-01 |
2011-02-28 |
이뮤노메딕스, 인코오포레이티드 |
내재화 항-cd74 항체 및 그 이용방법
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US7563433B2
(en)
*
|
2007-01-11 |
2009-07-21 |
Immunomedics, Inc. |
Methods and compositions for F-18 labeling of proteins, peptides and other molecules
|
|
US7597876B2
(en)
*
|
2007-01-11 |
2009-10-06 |
Immunomedics, Inc. |
Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
|
|
US7993626B2
(en)
*
|
2007-01-11 |
2011-08-09 |
Immunomedics, Inc. |
Methods and compositions for F-18 labeling of proteins, peptides and other molecules
|
|
US7651689B2
(en)
*
|
2002-11-15 |
2010-01-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Methods of applying ionization radiation for therapy of infections
|
|
JP4874090B2
(ja)
*
|
2003-01-31 |
2012-02-08 |
イミューノメディクス、インコーポレイテッド |
治療薬および診断薬を投与するための方法および組成物
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US20110171126A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US20170088635A1
(en)
*
|
2004-02-13 |
2017-03-30 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US7878978B2
(en)
|
2004-03-18 |
2011-02-01 |
University Of Pittsburgh- Of The Commonwealth System Of Higher Education |
Use of relaxin to increase arterial compliance
|
|
CA2563796A1
(en)
*
|
2004-04-23 |
2005-11-24 |
The University Of Georgia Research Foundation, Inc. |
Diagnostic assay for trypanosoma cruzi infection
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
CN101171034B
(zh)
|
2005-03-03 |
2014-06-18 |
免疫医疗公司 |
人源化l243抗体
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US20080171067A1
(en)
*
|
2007-01-17 |
2008-07-17 |
Immunomedics, Inc. |
Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
CA2604032C
(en)
*
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
CA2606081C
(en)
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
US7780969B2
(en)
*
|
2005-07-15 |
2010-08-24 |
University Of Georgia Research Foundation, Inc. |
Trypanosoma cruzi proteome compositions and methods
|
|
US20090042235A1
(en)
*
|
2005-08-19 |
2009-02-12 |
Shun Hirota |
Photoregulated peptide, and method for regulation of peptide-protein complex formation using the photoregulated peptide
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
CA2607056C
(en)
*
|
2005-10-19 |
2015-11-24 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
US8883162B2
(en)
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
CN105709237A
(zh)
*
|
2005-12-16 |
2016-06-29 |
Ibc 医药公司 |
基于免疫球蛋白的多价生物活性装配体
|
|
US20090110680A1
(en)
*
|
2006-04-07 |
2009-04-30 |
Stephanie Sieger |
Combination of an anti ED-B fibronectin domain antibody and gemcitabine
|
|
JP2009535372A
(ja)
*
|
2006-05-03 |
2009-10-01 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
抗edbフィブロネクチンドメイン抗体l19−sip及び抗−egfr−抗体の組合せ
|
|
WO2008001802A1
(en)
|
2006-06-27 |
2008-01-03 |
Asahi Kasei Kabushiki Kaisha |
Substrate for biological fluid treatment
|
|
WO2012024223A2
(en)
*
|
2010-08-17 |
2012-02-23 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
US8545809B2
(en)
|
2007-01-11 |
2013-10-01 |
Immunomedics, Inc. |
Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
|
|
US8398956B2
(en)
|
2007-01-11 |
2013-03-19 |
Immunomedics, Inc. |
In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
|
|
US8153100B2
(en)
*
|
2007-01-11 |
2012-04-10 |
Immunomedics, Inc. |
Methods and compositions for F-18 labeling of proteins, peptides and other molecules
|
|
US8709382B2
(en)
|
2007-01-11 |
2014-04-29 |
Immunomedics, Inc. |
Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
|
|
US8889100B2
(en)
|
2007-01-11 |
2014-11-18 |
Immunomedics, Inc. |
Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
|
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
|
|
EP2684889A3
(en)
*
|
2007-02-02 |
2014-03-05 |
Baylor Research Institute |
Multivariable antigens complexed with targeting humanized monoclonal antibody
|
|
WO2008137120A1
(en)
*
|
2007-05-03 |
2008-11-13 |
Tethys Bioscience, Inc. |
Binding reagents that contain small epitope binding molecules
|
|
JP5263805B2
(ja)
*
|
2007-06-13 |
2013-08-14 |
国立大学法人群馬大学 |
両親媒性の高分子配位子によって安定化された高分子錯体および検査用組成物および医薬組成物
|
|
EP2182979A4
(en)
*
|
2007-07-30 |
2010-09-08 |
Univ Georgia |
DIAGNOSTIC ASSAY FOR AN INFECTION WITH TRYPANOSOMA CRUZI
|
|
ES2536772T3
(es)
*
|
2007-09-21 |
2015-05-28 |
The Regents Of The University Of California |
El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
|
|
EP3524619A1
(en)
|
2007-12-06 |
2019-08-14 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
|
US9078864B2
(en)
|
2008-01-08 |
2015-07-14 |
Akthelia Pharmaceuticals |
Agonists for antimicrobial peptide systems
|
|
US8609437B2
(en)
*
|
2008-01-17 |
2013-12-17 |
The Institue for Cancer Research |
Biomarkers for the diagnosis and treatment of pancreatic cancer
|
|
US8034396B2
(en)
|
2008-04-01 |
2011-10-11 |
Tyco Healthcare Group Lp |
Bioadhesive composition formed using click chemistry
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
EP2282769A4
(en)
*
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
AU2009246333B2
(en)
*
|
2008-05-16 |
2013-05-09 |
Corthera, Inc. |
Method of promoting wound healing
|
|
US20090285757A1
(en)
*
|
2008-05-16 |
2009-11-19 |
Northeastern University |
Methods of targeting cells for diagnosis and therapy
|
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
LT2285408T
(lt)
|
2008-06-05 |
2019-01-25 |
Ablynx N.V. |
Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
|
|
EP2305309A2
(en)
|
2008-06-13 |
2011-04-06 |
Proyecto de Biomedicina Cima, S.L. |
Conjugates for the administration of biologically active compounds
|
|
US8822645B2
(en)
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
WO2010022225A1
(en)
*
|
2008-08-20 |
2010-02-25 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
US10407513B2
(en)
*
|
2008-09-26 |
2019-09-10 |
Ucb Biopharma Sprl |
Biological products
|
|
WO2010038228A2
(en)
*
|
2008-10-02 |
2010-04-08 |
Ramot At Tel Aviv University Ltd. |
Method and system for emitting light
|
|
MX2011005915A
(es)
|
2008-12-03 |
2011-08-17 |
Proyecto Biomedicina Cima Sl |
Uso de modulinas solubles en fenol para el desarrollo de vacunas.
|
|
US9125949B2
(en)
*
|
2008-12-30 |
2015-09-08 |
University Of North Texas |
Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials
|
|
WO2010090452A2
(ko)
*
|
2009-02-04 |
2010-08-12 |
성균관대학교산학협력단 |
세포 내 전달능이 증가된 작은 간섭 rna 복합체
|
|
PL3912643T3
(pl)
|
2009-02-13 |
2023-01-23 |
Immunomedics Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
|
EP2398584A2
(en)
|
2009-02-21 |
2011-12-28 |
Sofradim Production |
Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
|
|
US8956603B2
(en)
|
2009-02-21 |
2015-02-17 |
Sofradim Production |
Amphiphilic compounds and self-assembling compositions made therefrom
|
|
US9039979B2
(en)
|
2009-02-21 |
2015-05-26 |
Sofradim Production |
Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
|
|
CA2753179A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Crosslinked fibers and method of making same by extrusion
|
|
US8877170B2
(en)
|
2009-02-21 |
2014-11-04 |
Sofradim Production |
Medical device with inflammatory response-reducing coating
|
|
US8535477B2
(en)
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
WO2010095052A2
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Compounds and medical devices activated with solvophobic linkers
|
|
EP2398523B1
(en)
|
2009-02-21 |
2018-04-04 |
Covidien LP |
Medical devices having activated surfaces
|
|
US8663689B2
(en)
|
2009-02-21 |
2014-03-04 |
Sofradim Production |
Functionalized adhesive medical gel
|
|
US9273191B2
(en)
|
2009-02-21 |
2016-03-01 |
Sofradim Production |
Medical devices with an activated coating
|
|
US8512728B2
(en)
|
2009-02-21 |
2013-08-20 |
Sofradim Production |
Method of forming a medical device on biological tissue
|
|
US8968733B2
(en)
|
2009-02-21 |
2015-03-03 |
Sofradim Production |
Functionalized surgical adhesives
|
|
CA2753171A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Crosslinked fibers and method of making same using uv radiation
|
|
EP2398524B1
(en)
|
2009-02-21 |
2017-07-12 |
Covidien LP |
Medical devices having activated surfaces
|
|
US8637074B2
(en)
*
|
2009-03-31 |
2014-01-28 |
Aphios Corporation |
Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product
|
|
EP2258398A1
(en)
|
2009-05-26 |
2010-12-08 |
Araclón Biotech, S. L. |
Albumin-amyloid peptide conjugates and uses thereof
|
|
CN102459332B
(zh)
*
|
2009-06-05 |
2015-08-19 |
埃博灵克斯股份有限公司 |
用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
|
|
EP2473187A4
(en)
*
|
2009-08-31 |
2015-09-16 |
Immunomedics Inc |
COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
|
|
MX2012002651A
(es)
*
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
ES2655687T3
(es)
|
2009-09-11 |
2018-02-21 |
Proyecto De Biomedicina Cima, S.L. |
Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
|
|
WO2011034660A1
(en)
*
|
2009-09-16 |
2011-03-24 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
AR078651A1
(es)
*
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
WO2011050263A2
(en)
*
|
2009-10-23 |
2011-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Systemic immunosuppression in the treatment of age related macular degeneration and diabetic retinopathy
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
IN2012DN02692A
(cg-RX-API-DMAC10.html)
*
|
2009-11-05 |
2015-09-04 |
Ct Molecular Med & Immunology |
|
|
CN101876658B
(zh)
*
|
2009-11-25 |
2013-08-28 |
华中科技大学 |
一种具有多价效应和纳米尺寸效应的多肽荧光探针的构建方法及其应用
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
IN2012DN03354A
(cg-RX-API-DMAC10.html)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
|
IN2012DN03177A
(cg-RX-API-DMAC10.html)
|
2009-12-04 |
2015-09-25 |
Immunomedics Inc |
|
|
CA2782527C
(en)
|
2009-12-04 |
2019-09-17 |
Oncoimmune Inc. |
Uses of hypoxia-inducible factor inhibitors
|
|
CN102665757A
(zh)
|
2009-12-09 |
2012-09-12 |
免疫医疗公司 |
通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
|
|
US20120259099A1
(en)
*
|
2009-12-15 |
2012-10-11 |
MuHyeon CHOE |
Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
CA2794336A1
(en)
|
2010-03-25 |
2011-09-29 |
Sofradim Production |
Surgical fasteners and methods for sealing wounds
|
|
US8795331B2
(en)
|
2010-03-25 |
2014-08-05 |
Covidien Lp |
Medical devices incorporating functional adhesives
|
|
EP2552483A4
(en)
*
|
2010-04-01 |
2013-09-25 |
Immunomedics Inc |
USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS
|
|
EP2588525A4
(en)
|
2010-06-29 |
2015-06-10 |
Covidien Lp |
MICROWAVE POWERED REACTOR AND IN SITU IMPLANT TRAINING METHOD
|
|
US8865857B2
(en)
|
2010-07-01 |
2014-10-21 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
WO2012014080A2
(en)
|
2010-07-27 |
2012-02-02 |
Sofradim Production |
Polymeric fibers having tissue reactive members
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
|
EP2635300A4
(en)
*
|
2010-11-03 |
2014-04-02 |
Ibc Pharmaceuticals Inc |
DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
|
|
WO2012123269A1
(en)
|
2011-03-11 |
2012-09-20 |
Proyecto De Biomedicina Cima, S.L. |
Immunogenic compositions and methods for their use
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
WO2012162583A1
(en)
*
|
2011-05-26 |
2012-11-29 |
Ibc Pharmaceuticals, Inc. |
Design and construction of novel multivalent antibodies
|
|
EP2729488A4
(en)
*
|
2011-07-06 |
2015-01-14 |
Medimmune Llc |
PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
EP2606897A1
(en)
|
2011-12-22 |
2013-06-26 |
Laboratorios Del. Dr. Esteve, S.A. |
Methods and compositions for the treatment of diseases caused by enveloped viruses
|
|
CN102559636B
(zh)
*
|
2011-12-30 |
2014-03-12 |
百泰生物药业有限公司 |
用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
MX2014015205A
(es)
|
2012-06-14 |
2015-08-14 |
Ambrx Inc |
Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
HK1218930A1
(zh)
|
2013-02-08 |
2017-03-17 |
Abbvie Stemcentrx Llc |
新型多特异性结构
|
|
WO2014143383A1
(en)
|
2013-03-13 |
2014-09-18 |
Agilent Technologies, Inc. |
Transposome tethered to a gene delivery vehicle
|
|
CN105530959B
(zh)
*
|
2013-03-15 |
2021-09-17 |
纪念斯隆-凯特琳癌症中心 |
多聚化技术
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
CN104650237B
(zh)
*
|
2013-06-28 |
2019-08-20 |
英科隆生物技术(杭州)有限公司 |
一种交联抗体及其在免疫检测中应用
|
|
CN103382224B
(zh)
*
|
2013-06-28 |
2015-03-18 |
英科隆生物技术(杭州)有限公司 |
含有四聚体形式的异源交联抗体的异源交联物及其应用
|
|
CA2924520C
(en)
|
2013-11-01 |
2023-09-26 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
|
|
CN103897064B
(zh)
*
|
2013-11-29 |
2016-05-11 |
广州优联康医药科技有限公司 |
长效重组人绒促性素融合蛋白
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
US11039621B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US11039620B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US9622483B2
(en)
|
2014-02-19 |
2017-04-18 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
ES2978993T3
(es)
|
2014-02-21 |
2024-09-23 |
Ibc Pharmaceuticals Inc |
Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
WO2015138638A1
(en)
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Long acting trail receptor agonists for treatment of autoimmune diseases
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
IL300029A
(en)
|
2014-05-16 |
2023-03-01 |
Baylor Res Institute |
Methods and preparations for the treatment of autoimmune and inflammatory conditions
|
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Cd33キメラ抗原受容体を使用する癌の処置
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
PL3204018T3
(pl)
|
2014-10-07 |
2022-01-03 |
Immunomedics, Inc. |
Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
AU2015366284B2
(en)
*
|
2014-12-19 |
2021-07-22 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
|
CN107250161A
(zh)
|
2015-01-26 |
2017-10-13 |
宏观基因有限公司 |
包含dr5‑结合结构域的多价分子
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
JP6803339B2
(ja)
|
2015-04-21 |
2020-12-23 |
エンリヴェックス セラピューティクス リミテッド |
治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
|
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN107614515B
(zh)
|
2015-05-28 |
2022-03-22 |
免疫医疗公司 |
用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
IL256833B2
(en)
*
|
2015-07-15 |
2025-07-01 |
California Inst Of Techn |
IL-17F-specific binding agents, compositions and methods of use and preparation
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
UA128469C2
(uk)
|
2015-10-08 |
2024-07-24 |
Макродженікс, Інк. |
Спосіб лікування в7-н3-експресуючого раку
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
CN108697794A
(zh)
|
2015-12-17 |
2018-10-23 |
诺华股份有限公司 |
C-met抑制剂和抗pd-1抗体分子的组合及其用途
|
|
US11007251B2
(en)
|
2015-12-17 |
2021-05-18 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN109195620B
(zh)
|
2016-04-07 |
2022-06-28 |
约翰霍普金斯大学 |
用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
|
|
CN109069633A
(zh)
|
2016-04-15 |
2018-12-21 |
宏观基因有限公司 |
新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
|
|
US20230071283A1
(en)
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
KR20230136699A
(ko)
|
2016-06-06 |
2023-09-26 |
노쓰웨스턴유니버시티 |
융합 단백질 작제물
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
KR20230100748A
(ko)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
WO2018027223A1
(en)
|
2016-08-05 |
2018-02-08 |
Duke University |
Camkk2 inhibitor compositions and methods of using the same
|
|
CN106267191A
(zh)
*
|
2016-09-03 |
2017-01-04 |
山西纳安生物科技有限公司 |
纳米抗体生物药透皮给药制剂系统及制备方法和应用
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
BR112019012950A2
(pt)
|
2016-12-23 |
2019-11-26 |
Macrogenics, Inc. |
molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
BR112019017628A2
(pt)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
ES2922003T3
(es)
*
|
2017-04-24 |
2022-09-06 |
Advanced Accelerator Applications |
Activador de neutrones impulsado por acelerador para braquiterapia
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
CA3062439A1
(en)
|
2017-05-05 |
2018-11-08 |
Memorial Sloan Kettering Cancer Center |
Modular self assembly disassembly (sada) technologies
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
|
TWI635559B
(zh)
*
|
2017-07-25 |
2018-09-11 |
春田科技顧問股份有限公司 |
裝載埠的吹淨裝置及其吹淨方法
|
|
EP3658589B1
(en)
|
2017-07-26 |
2023-09-27 |
Forty Seven, Inc. |
Anti-sirp-alpha antibodies and related methods
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
US11795226B2
(en)
|
2017-12-12 |
2023-10-24 |
Macrogenics, Inc. |
Bispecific CD16-binding molecules and their use in the treatment of disease
|
|
KR20240134250A
(ko)
|
2018-01-04 |
2024-09-06 |
아이코닉 테라퓨틱스, 인코포레이티드 |
항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
TW202311746A
(zh)
*
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
EP3759225A1
(en)
|
2018-03-02 |
2021-01-06 |
Sixfold Bioscience Ltd. |
Compositions for delivery of cargo to cells
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019183131A1
(en)
|
2018-03-19 |
2019-09-26 |
Bioventures, Llc |
Periostin antibodies and methods of using the same
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US12128099B2
(en)
|
2018-05-25 |
2024-10-29 |
Bioventures, Llc |
Myxoma virus compositions and methods of use
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
JP2022532812A
(ja)
|
2018-08-16 |
2022-07-20 |
カンタージア アクチエボラーグ |
抗il1rap抗体組成物
|
|
JP7497351B2
(ja)
|
2018-11-13 |
2024-06-10 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
チェックポイント分子に対する多重特異性結合性構築物およびその使用
|
|
US12428626B2
(en)
|
2018-11-20 |
2025-09-30 |
Bioventures, Llc |
Cells for the production of viruses and methods of using the same
|
|
US20210386763A1
(en)
|
2018-12-20 |
2021-12-16 |
Novartis Ag |
Pharmaceutical combinations
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
|
EP3927371A1
(en)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
PH12021552414A1
(en)
|
2019-03-29 |
2022-07-25 |
Atarga Llc |
Anti fgf23 antibody
|
|
EP4004037A1
(en)
|
2019-07-26 |
2022-06-01 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
|
MX2022001942A
(es)
*
|
2019-08-15 |
2022-07-27 |
Regeneron Pharma |
Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
|
|
US12252582B2
(en)
|
2019-08-29 |
2025-03-18 |
University Of Delaware |
Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
|
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
|
KR20220140568A
(ko)
|
2020-02-11 |
2022-10-18 |
벤더르빌트 유니버시티 |
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
|
|
JP7745556B2
(ja)
|
2020-02-21 |
2025-09-29 |
マクロジェニクス,インコーポレーテッド |
Cd137結合分子及びその使用
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
WO2021195418A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
CN115997016A
(zh)
|
2020-04-27 |
2023-04-21 |
西克斯福德生物科学有限公司 |
包含具有模块化官能团的核酸纳米颗粒的组合物
|
|
CN111500586B
(zh)
*
|
2020-05-21 |
2022-11-04 |
昆明理工大学 |
特异结合狂犬病毒l蛋白加帽区的核酸适配体及其应用
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2022000136A1
(en)
*
|
2020-06-28 |
2022-01-06 |
Dingfu Biotarget Co., Ltd. |
Methods and compositions for cancer treatment
|
|
US20240279353A1
(en)
|
2020-07-06 |
2024-08-22 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
CA3176556A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
CN112156194B
(zh)
*
|
2020-09-29 |
2023-01-24 |
中国工程物理研究院核物理与化学研究所 |
一种去除177Lu溶液中内毒素的方法
|
|
WO2022082030A2
(en)
|
2020-10-15 |
2022-04-21 |
Gritstone Bio, Inc. |
Antigen-binding proteins and related methods of use
|
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
KR20230107617A
(ko)
|
2020-11-13 |
2023-07-17 |
노파르티스 아게 |
키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
|
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
WO2022155503A1
(en)
|
2021-01-14 |
2022-07-21 |
Gritstone Bio, Inc. |
Multi-specific antibodies and methods of use
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN113403384A
(zh)
*
|
2021-06-22 |
2021-09-17 |
南昌大学 |
动脉粥样硬化生物标志物及其应用
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CN118541392A
(zh)
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|
|
US20250084155A1
(en)
|
2021-09-29 |
2025-03-13 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CA3263767A1
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
|
|
CN116444668B
(zh)
*
|
2022-08-24 |
2026-04-21 |
龙湖现代免疫实验室 |
一种量子点标记的丙酸睾酮直接竞争荧光免疫检测方法
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|
|
WO2026042013A1
(en)
|
2024-08-19 |
2026-02-26 |
Institute Of Molecular And Clinical Ophthalmology Basel (Iob) |
Mitochondrial therapy
|
|
US20260167709A1
(en)
|
2024-09-11 |
2026-06-18 |
Novartis Ag |
Antibodies targeting il-31
|
|
WO2026102093A1
(en)
|
2024-11-07 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2026151679A1
(en)
|
2025-01-07 |
2026-07-16 |
Compass Therapeutics, Llc. |
Multispecific binding constructs targeting pd-1 and vegf and uses thereof
|